DDInter1951 DDInter899
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Warfarin {u} (Compound) resembles {v} (Compound) Benzyl Benzoate
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Warfarin {u} (Compound) resembles {v} (Compound) Fenoprofen
Warfarin {u} (Compound) binds {v} (Gene) CYP2C8
Warfarin {u} (Compound) upregulates {v} (Gene) CDK6
Warfarin {u} (Compound) is included by {v} (Pharmacologic Class) Vitamin K Inhibitors
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Meloxicam
Warfarin (Compound) resembles Benzyl Benzoate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Warfarin (Compound) resembles Fenoprofen (Compound)
Warfarin (Compound) binds CYP2C8 (Gene)
Warfarin (Compound) upregulates CDK6 (Gene)
Warfarin (Compound) is included by Vitamin K Inhibitors (Pharmacologic Class)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Warfarin may lead to a major life threatening interaction when taken with Meloxicam